Albert Bourla, Pfizer CEO (AP Images)
Pfizer/BioNTech makes surprise choice in final dash to October finish line for Covid-19 vaccine
Pfizer and BioNTech have zeroed in on an mRNA vaccine candidate to take into a pivotal study — and it’s not the one that got analysts …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
